A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children

Phase 3

Recruiting

• Conditions: Myopia
• Interventions: Drug: QLM3004 Concentration 1; Drug: QLM3004 Concentration 2; Drug: QLM3004 Concentration 3; Other: Placebo

• Registration Number: NCT06151587
• Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Brief Summary

Efficacy and Safety Study of QLM3004 in Myopic Children

Detailed Description

The study was divided into 2 phases, with Stage 1 being the primary efficacy and safety confirmation phase and Stage 2 a post-withdrawal observation period.

Stage 1:To evaluate the safety and efficacy of 3 concentrations of QLM3004 compared to Vehicle (placebo)for slowing the progression of myopia in children over a 96-week treatment period.

Stage 2:subjects will enter Period 2 of the study, and Period 2 will be a post-withdrawal observation period, which will not serve as a validation basis for the efficacy and safety of QLM3004.

Study Timeline

• Study Start: 2023-08-20
• Status Verified: 2023-11
• Study First Submitted: 2023-11-20
• Study First Submitted QC: 2023-11-21
• Last Update Submitted: 2023-11-21
• Study First Posted: 2023-11-30
• Last Update Posted: 2023-11-30
• Primary Completion: 2026-06
• Study Completion: 2027-06

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 735

Inclusion Criteria

• Age 6 to 12 years
• Myopia -1.00D to -4.00D spherical equivalent (SE) in both eyes as measured by cycloplegic autorefraction.
• Astigmatism ≤1.50 D in both eyes.
• Anisometropia ≤1.50 D SE.
• Informed consent signed by the subjects and/or their legal representatives

Exclusion Criteria

• Suffering from serious systemic diseases
• Any eye disease that affect vision or refractive error
• Current or prior history of manifest strabismus, amblyopia, or other ocular pathologic changes
• Acute inflammatory disease or active infection of the eye in either eye, or a history of chronic ocular inflammation or recurrent episodes of ocular inflammation
• Best corrected distance visual acuity in both eyes<4.9
• Abnormal intra-ocular pressure (>21 mmHg or difference between two eyes >5mmHg)
• Current or previous form of myopia control, including but not limited to drugs, orthokeratology, progressive addition lenses, bifocal lenses, etc.
• Systemic or topical use of medications within 3 months that interfere with efficacy evaluation (excluding optometry)
• Allergy or hypersensitivity to atropine, excipients, cyclopentolate or fluorescein sodium
• Participants for whom the clinical significance of ophthalmologic examination abnormalities indicate that one or both eyes are not suitable candidates for treatment based upon the Investigator's medical judgment
• Participation of the drug clinical trial within three month and the device clinical trial within one month
• Anticipated long-term use of ocular or systemic oral corticosteroids during the study period
• Any other condition not suitable for the study per investigator's judgement

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
QLM3004 Concentration 1	QLM3004 Concentration 1	Solution low dose
QLM3004 Concentration 2	QLM3004 Concentration 2	Solution medium dose
QLM3004 Concentration 3	QLM3004 Concentration 3	Solution high dose
Placebo	Placebo	Placebo Ophthalmic Solution

Primary Outcome Measures

Name	Time	Method
Change from Baseline in spherical equivalent determined by cycloplegic autorefraction at week 96.	96 week	Effectiveness Evaluation

Trial Locations

Locations (1)

The Affiliated Eye Hospital of Wenzhou Medical University; 🇨🇳 Wenzhou, Zhejiang, China